Catheter Precision, Inc. (VTAK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Catheter Precision, Inc. on July 3, 2024, covering events occurring on July 1 and July 2, 2024. The Company, incorporated in Delaware, operates in the medical device sector and trades on the NYSE American under the symbol VTAK.
Key Financial Metrics and Capital Structure
The filing references a press release (Exhibit 99.1) containing preliminary unaudited revenue for the second quarter and six months ended June 30, 2024. However, the text of this 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity.
Regarding capital structure, the Company issued 814,228 shares of common stock on July 2, 2024, resulting from the conversion of 1,303 shares of Series A Convertible Preferred Stock. The conversion ratio was approximately 625 common shares for each preferred share.
Material Changes and Corporate Actions
- Reverse Stock Split: The Company approved a 1-for-10 reverse stock split, effective July 15, 2024, at 12:01 A.M. Eastern Time. This action reduces the number of issued common shares from 8,387,631 to approximately 838,763.
- Stockholder Approval: At a special meeting on July 3, 2024, stockholders granted the Board discretion to effect a split between 1-for-5 and 1-for-15; the Board selected the 1-for-10 ratio.
- Fractional Shares: No fractional shares will be issued. Stockholders entitled to fractional shares will receive cash proceeds from the sale of aggregated fractional shares.
- Adjustments: Proportional adjustments will be made to equity awards, warrants, and convertible securities, including exercise prices.
Outlook, Risks, and Contingencies
The Company reserves the right to abandon the reverse stock split at any time prior to its effectiveness, noting there is no guarantee it will become effective. The new CUSIP number following the split will be 74933X 609. The filing does not contain specific management commentary on future financial guidance or operational risks beyond the execution of the stock split.
Key Facts for Investor Verification
- Verify the specific revenue and financial performance figures in the attached Press Release (Exhibit 99.1), as they are not detailed in the 8-K text.
- Confirm the effective date and time of the 1-for-10 reverse stock split (July 15, 2024, 12:01 A.M. ET) and the new CUSIP number (74933X 609).
- Review the impact of the reverse split on existing holdings, specifically regarding the treatment of fractional shares and the adjustment of warrant exercise prices.
- Monitor the Company's announcement regarding the finalization of the reverse split, as it may be abandoned prior to the effective date.